On Tuesday shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed at $11.01. Company’s sales growth for last 5 years was -54.90%. On March 20, Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate — oral small molecule pharmacological chaperone migalastat HCl. The candidate is being developed as a monotherapy for Fabry patients who have amenable genetic mutations.
On Tuesday shares of Apple Inc. (NASDAQ:AAPL) closed at $126.69. Company’s sales growth for last 5 years was 33.60% and EPS growth for next 5 years is recorded as 12.96%. There have been rumors that Apple Inc. (NASDAQ:AAPL) is working on a new 12-inch iPad, dubbed Apple iPad Pro and also referred to as iPad Plus, which will compete with the Microsoft Surface 12-inch tablet, as well as various Samsung 12-inch tablets currently available in the market. Apple has not yet confirmed or denied this rumor, but the latest 3D renders of the tablet have further added to the hype surrounding the company’s upcoming new 12-inch iPad.
On last trading day Primerica, Inc. (NYSE:PRI) fell -0.54% to close at $51.43. Its volatility for the week is 2.16% while volatility for the month is 1.65%. PRI’s sales growth for past 5 years was -9.60% and its EPS growth for past 5 years was -12.70%. Primerica, Inc. (NYSE:PRI) monthly performance is -2.13%. Primerica Inc. (NYSE:PRI) was recently recognized by the Atlanta Journal-Constitution as one of the best workplaces in Georgia. Primerica was the highest ranking public company headquartered in Georgia, and it ranked 7th out of 25 companies in the “large companies” category (500+ employees in Georgia) when compared with private companies and non-profit organizations.
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has 9.30% insider ownership while its institutional ownership stands at 61.70%. In last trading activity company’s stock closed at $21.07. La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced that it has initiated its ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, a Phase 3 clinical trial of LJPC-501for the treatment of catecholamine-resistant hypotension (CRH).
JA Solar Holdings Co., Ltd. (NASDAQ:JASO) in last trading activity moved up 2.85% to close at $10.09. Company weekly performance is 6.21% while its quarterly performance stands at 29.03%. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) is -13.61% away from its 52 week high. JA Solar Holdings Co. (NASDAQ:JASO) was downgraded by Zacks from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday. They currently have a $9.75 target price on the stock. Zacks‘s price target points to a potential downside of 0.61% from the company’s current price.